{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:52Z","timestamp":1791357472462,"version":"4.3.1"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,11,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Atomoxetine is an investigational, nonstimulant pharmacotherapy being studied as potential treatment for attention-deficit\/hyperactivity disorder (ADHD). It is thought to act via blockade of the presynaptic norepinephrine transporter in the brain. We assessed the efficacy of 3 doses of atomoxetine compared with placebo in children and adolescents with ADHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A total of 297 children and adolescents who were 8 to 18 years of age and had ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, were randomized to placebo or atomoxetine dosed on a weight-adjusted basis at 0.5 mg\/kg\/day, 1.2 mg\/kg\/day, or 1.8 mg\/kg\/day for an 8-week period. ADHD symptoms, affective symptoms, and social and family functioning were assessed using parent and investigator rating scales.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Approximately 71% of children enrolled were male, approximately 67% met criteria for mixed subtype (both inattentive and hyperactive\/impulsive symptoms), and the only common psychiatric comorbidity was oppositional defiant disorder (approximately 38% of the sample). At baseline, symptom severity was rated as moderate to severe for most children. At endpoint, atomoxetine 1.2 mg\/kg\/day and 1.8 mg\/kg\/day were consistently associated with superior outcomes in ADHD symptoms compared with placebo and were not different from each other. The dose of 0.5 mg\/kg\/day was associated with intermediate efficacy between placebo and the 2 higher doses, suggesting a graded dose-response. Social and family functioning also were improved in the atomoxetine groups compared with placebo with statistically significant improvements in measures of children's ability to meet psychosocial role expectations and parental impact. Discontinuations as a result of adverse events were &amp;lt;5% for all groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms. Atomoxetine was associated with a graded dose-response, and 1.2 mg\/kg\/day seems to be as effective as 1.8 mg\/kg\/day and is likely to be the appropriate initial target dose for most patients. Treatment with atomoxetine was safe and well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.108.5.e83","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"e83-e83","source":"Crossref","is-referenced-by-count":525,"title":["Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit\/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study"],"prefix":"10.1542","volume":"108","author":[{"given":"David","family":"Michelson","sequence":"first","affiliation":[{"name":"From the Lilly Research Laboratories and"},{"name":"Indiana University School of Medicine, Indianapolis, Indiana;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Faries","sequence":"additional","affiliation":[{"name":"From the Lilly Research Laboratories and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Wernicke","sequence":"additional","affiliation":[{"name":"From the Lilly Research Laboratories and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kelsey","sequence":"additional","affiliation":[{"name":"From the Lilly Research Laboratories and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kendrick","sequence":"additional","affiliation":[{"name":"From the Lilly Research Laboratories and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Randy","family":"Sallee","sequence":"additional","affiliation":[{"name":"University of Cincinnati, Cincinnati, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Spencer","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Atomoxetine ADHD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2001,11,1]]},"reference":[{"key":"2021121003521078700_B1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1542\/peds.105.5.1158","article-title":"Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit\/hyperactivity disorder.","volume":"105","author":"American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on Attention-Deficit\/Hyperactivity Disorder","year":"2000","journal-title":"Pediatrics"},{"key":"2021121003521078700_B2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1056-4993(18)30102-0","article-title":"Assessment and diagnosis of attention-deficit\/hyperactivity disorder.","volume":"9","author":"Hechtman","year":"2000","journal-title":"Child Adolesc Psychiatr Clin North Am"},{"key":"2021121003521078700_B3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1207\/s15374424jccp1503_1","article-title":"Hyperactivity at adolescence: some misconceptions and new directions.","volume":"15","author":"Brown","year":"1986","journal-title":"J Clin Child Psychol"},{"key":"2021121003521078700_B4"},{"key":"2021121003521078700_B5"},{"key":"2021121003521078700_B6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00004583-199105000-00005","article-title":"Long-term outcome of hyperactive children: a review.","volume":"30","author":"Klein","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121003521078700_B7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1037\/0033-2909.96.1.116","article-title":"Review of follow-up and follow-back studies of childhood hyperactivity.","volume":"96","author":"Thorley","year":"1984","journal-title":"Psychol Bull"},{"key":"2021121003521078700_B8"},{"key":"2021121003521078700_B9"},{"key":"2021121003521078700_B10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archpsyc.56.12.1073","article-title":"A 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder.","volume":"56","author":"MTA Cooperative Group","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"2021121003521078700_B11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00004583-200102000-00012","article-title":"Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.","volume":"40","author":"Greenhill","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121003521078700_B12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1542\/peds.98.4.748","article-title":"Methylphenidate dosing: twice daily versus three times daily.","volume":"98","author":"Stein","year":"1996","journal-title":"Pediatrics"},{"key":"2021121003521078700_B13","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/00004583-199611000-00017","article-title":"A naturalistic assessment of protriptyline for attention-deficit hyperactivity disorder.","volume":"35","author":"Wilens","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121003521078700_B14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/ajp.147.8.1018","article-title":"Bupropion treatment of attention-deficit hyperactivity disorder in adults.","volume":"147","author":"Wender","year":"1990","journal-title":"Am J Psychiatry"},{"key":"2021121003521078700_B15","first-page":"15","article-title":"A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder.","volume":"48","author":"Higgins","year":"1999","journal-title":"J Fam Pract"},{"key":"2021121003521078700_B16"},{"key":"2021121003521078700_B17"},{"key":"2021121003521078700_B18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1176\/ajp.155.5.693","article-title":"Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.","volume":"155","author":"Spencer","year":"1998","journal-title":"Am J Psychiatry"},{"key":"2021121003521078700_B19"},{"key":"2021121003521078700_B20"},{"key":"2021121003521078700_B21"},{"key":"2021121003521078700_B22"},{"key":"2021121003521078700_B23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/A:1008810004694","article-title":"Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results.","volume":"7","author":"Landgraf","year":"1998","journal-title":"Qual Life Res"},{"key":"2021121003521078700_B24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00004583-199301000-00029","article-title":"Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome.","volume":"32","author":"Spencer","year":"1993","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121003521078700_B25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004583-199303000-00015","article-title":"Nortriptyline in the treatment of ADHD: a chart review of 58 cases.","volume":"32","author":"Wilens","year":"1993","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121003521078700_B26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00004583-199303000-00006","article-title":"A retrospective study of serum levels and electrocardiographic effects of nortriptyline in children and adolescents.","volume":"32","author":"Wilens","year":"1993","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121003521078700_B27"},{"key":"2021121003521078700_B28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1056-4993(18)30111-1","article-title":"Psychosocial interventions: individual psychotherapy with the child, and family interventions.","volume":"9","author":"Stubbe","year":"2000","journal-title":"Child Adolesc Psychiatr Clin North Am"},{"key":"2021121003521078700_B29","doi-asserted-by":"crossref","first-page":"85S","DOI":"10.1097\/00004583-199710001-00007","article-title":"Practice parameters for the assessment and treatment of children, adolescents and adults with attention-deficit\/hyperactivity disorder.","volume":"35","author":"Dulcan","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121003521078700_B30"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/5\/e83\/893121\/pe1101000jl1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/5\/e83\/893121\/pe1101000jl1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T05:06:07Z","timestamp":1705208767000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/108\/5\/e83\/63678\/Atomoxetine-in-the-Treatment-of-Children-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,1]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2001,11,1]]},"published-print":{"date-parts":[[2001,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.108.5.e83","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11,1]]}}}